1.廣東省第五屆專利獎優秀獎（2018）

2.廣東特支計劃“科技創新領軍人才”(2016)

發表的主要一作或通訊作者文章

[1]Zhang N, Liu Z, Liang J, Tang Y, Qian Lu, Gao Y,Zhang T*, Ming Yan*. Design, synthesis, and biological evaluation of m-amido phenol derivatives as a new class of antitubercular agents.Med Chem Comm(Accepted)

[2] Liu P, Yang Y, Ju Y, Tang Y, Sang Z, Chen L, Yang T, An Q,Zhang T, Luo Y*. Design, synthesis and biological evaluation of novel pyrrole derivatives as potential ClpP1P2 inhibitor against.Mycobacterium tuberculosis.Bioinorganic Chemistry原來名稱：Journal of inorganic biochemistry(Accepted).

[3]Chhotaray C, Tan Y, Mugweru J, Hameed H.M. A., Islam M.M, Wang S, Lu Zh, Wang C, Li X, Tan S, Liu J*,Zhang T*. Advances in development of molecular genetic tools inMycobacterium tuberculosis.J Genet Genomics. 2018, 45: 281-297.

[4] Mugweru J, Liu J, Makafe Gaelle, Chiwala G, Wang B, Wang C, Li X, Tan Y, Yew W, Tan S*,Zhang T*.MutationethAW21RConfers Co-resistance to Protionamide and Ethionamide in bothM. bovisBCG andM. tuberculosisH37Rv.Infect Drug Resist.2018, 11: 891-894.

[5]Hameed A, Islam M, Chhotaray C, Liu Y, Tan Y, Li X, Tan S, Chen L, Delorme V, Yew W, Liu J*,Zhang T*.Molecular targets related drug resistance mechanisms in MDR-, XDR- and TDR-Mycobacterium tuberculosisstrains.Front Cell Infect Microbiol.2018, 8:114.

[6]Njire M, Wang N, Wang B, Tan Y, Cai X, Julius M, Cai X, Liu Y, Mugweru J, Guo J, Hameed HMA, Tan S, Liu J, Yew W, Nuermberger EL, Lamichhane G, Liu J,Zhang T*.Pyrazinoic Acid Inhibits a Bifunctional Enzyme inMycobacterium tuberculosis.Antimicrob Agents Chemother.2017，61(7)：e00070-17.

[7] Mugweru J, Makafe G, Cao Y, Zhang Y, Wang B, Huang S, Njire M, Chotorary C, Tan Y, Li X, Liu J, Tan S, Deng J,Zhang T*.A Cassette Containing Thiostrepton, Gentamicin Resistance Genes anddifsequences is Effective in Construction of Recombinant Mycobacteria.Front Microbiol.2017, 8:468

[8] Islam M, Hameed A, Mugweru J, Chhotaray C, Wang C, Tan Y, Liu J, Li X, Tan S, Ojima I, Yew W,Zhang T*.Drug Resistance Mechanisms and Novel Drug Targets for Tuberculosis Therapy.J Genet Genomics. 2017, 44:21-37.

[9]Guo J, Wang C, Han Y, Liu Z, Wu T, Liu Y, Liu Y, Tan Y, Cai X, Cao Y, Wang B, Zhang B, Liu C, Tan S andZhang T*.Identification of Lysine Acetylation inMycobacterium abscessusUsing LC-MS/MS after Immunoprecipitation.J Proteome Res.2016. 15(8):2567-2578. (DOI: 10.1021/acs.jproteome.6b00116).

[10] Tan S*, Rao Y, Guo J, Tan Y, Cai X, Kuang H, Li Y, Liu W, Mugweru J, Wang B, Cao Y, Wang C, Zhang Y,Zhang T*.The Influence of Pyrazinamide Monoresistance on Treatment Outcomes in Tuberculosis Patients from Southern China.J Tuberculosis Res.2016.4:9-17.

[11]Makafe G, Cao Y, TanY, Julius M, Liu Z,Wang C, Njire M, Cai X,Liu T,Wang B, Pang W, Tan S, ZhangB, Yew W, Lamichhane G, Guo J,Zhang T*.Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance inMycobacterium tuberculosis.Antimicrob Agents Chemother.2016.60(5):3202-3206.

[12] Njire M, Tan Y, Mugweru J, Wang C, Guo J, Yew W, Tan S*,Zhang T*.Pyrazinamide resistance inMycobacterium tuberculosis: review and update.Adv Med Sci.2016. 61(1):63-71.

[13]Tang J, Wang B, Wu T, Wan J, Tu Z, Njire M, Wan B, Franzblauc SG,Zhang T*, Lu X*, Ding K*. Design, synthesis and biological evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as novel antitubercular agents.ACS Med Chem Lett. 2015. 6:814-818.

[14] Liu T, Wang B, Guo J, Zhou Y, Julius M, Njire M, Cao Y, Wu T, Liu Z, Wang C, Xu Y,Zhang T*.Role offolp1andfolp2genes in the action of sulfamethoxazole and trimethoprim against mycobacteria.J Microbiol Biotechnol.2015. 25(9):1559-1567.

[15] Yang F, Njire M, Liu J, Wu T, Wang B, Liu T, Cao Y, Liu Z, Wan J, Tu Z, Tan Y, Tan S,Zhang T*. Engineering more stable, selectable marker-free autoluminescent mycobacteria by one step.PLoS One. 2015. 10(1):e0119341.

[16] Yang F, Tan YJ, Liu J, Liu TZ, Wang BX, Cao YY, Qu Y, Lithgow T, Tan SY,Zhang T*. Efficient construction of unmarked recombinant mycobacteria using an improved system.J Microbiol Methods. 2014. 103:29-36.

[17] Tan YJ, Hu ZQ,Zhang T*, Cai XS, Kuang HB, Liu YW, Chen JY, Yang F, Zhang K, Tan SY*, Zhao YL. Role ofpncAandrpsAgene sequencing in detection of pyrazinamide resistance inMycobacterium tuberculosisisolates from southern China.J Clin Microbiol. 2014. 52(1):291-297.

[18]Tan S*, Sun D, Zhang T, Li Y, Cao Y,Njire M, Wang C,Zhang T*. Risk factors for hemoptysis in pulmonary tuberculosis patients from southern China: a retrospective study.J Tuberculosis Res.2014. 2:173-180.

[19]Zhang T,Li SY, Converse PJ, Grosset JH, Nuermberger EL*. Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescentMycobacterium ulceransinfection.PLoS Negl Trop Dis.2013.7(12):e2598.

[20] Chen C, Lu M, Liu Z, Wan J, Tu Z,Zhang T*,Yan M*. Synthesis and evaluation of 2-amino-4h-pyran-3-carbonitrile derivatives as antitubercular agents.Open J Med Chemi.2013. 3: 128-135.

[21]Zhang T, Li SY, Nuermberger EL*. AutoluminescentMycobacterium tuberculosisfor rapid, real-time, non-invasive assessment of drug and vaccine efficacy.PLoS One.2012. 7:e29774.

[22]Zhang T, Li SY, Williams KN, Andries K, Nuermberger EL*.Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.Am J Respir Crit Care Med.2011. 184:732-737.

[23]Zhang T, Li SY, Converse PJ, Almeida DV, Grosset JH, Nuermberger EL*.Using bioluminescence to monitor treatment response in real time in mice withMycobacterium ulceransinfection.Antimicrob Agents Chemother.2011. 55:56-61.

[24]Zhang T,Bishai WR, Grosset JH, Nuermberger EL*. Rapid assessment of antibacterial activity againstMycobacterium ulceransby using recombinant luminescent strains.Antimicrob Agents Chemother.2010. 54(7): 2806-2813.

[25]Zhang T,Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL*. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.Am J Respir Crit Care Med. 2009. 180: 1151-1157.

[26]Zhang T,Wang L，Xu G，Chen Y，Zhang Y，Li Y*. Disruption ofste23gene affects composition profile and bioactivity of exopolysaccharide produced byStreptomycessp. 139.Lett App Microbiol. 2006, 42(2):132-137.

[27]Zhang T,Wang L，Xu G，Chen Y，Zhang Y，Li Y*. Disruption of theste22Gene Encoding a Glycosyltransferase and Its Function in Biosynthesis of Ebosin inStreptomycessp. 139.Curr Microbiol.2006, 52(1):55-59.

[28]劉誌永，王帥，張天宇*，土井教生，譚守勇，謝小保，高亞敏，唐運祥，薑火風，謝武。一種新型醫用動態空氣消毒機對MTB等病原微生物殺菌效果的研究。中國防癆雜誌。2018，40（4）：411-415。

[29]劉洋，王邦興，劉誌永，韓軼，譚耀駒，李昕潔，劉健雄，譚守勇*，張天宇*。非一線抗結核藥物耐藥機製及耐藥性診斷研究進展。遺傳。2016，38 (10):928-939。

[30]張天宇，謝建平，王明貴。抗生物耐藥性研究領域的機遇和挑戰。遺傳。2016，38 (10):857-858。

[31]梁鎮興,張可,譚耀駒,譚守勇,張天宇*。利用自主發光結核分枝杆菌快速連續檢測抗結核藥物的細胞內活性。實用醫學雜誌。2013，29 (23): 209-212。

已發表的主要共同作者文章 （僅列出2014年後的）

[1]Wang T, Tang Y, Yang Y, An Q, Sang Z, Yang T, Liu P,Zhang T, Deng Y, LuoY.Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.Bioorg Med Chem Lett. 2018, 28(11): 2084-2090.

[2] Feng P, Ma G,Zhang T, Wang C. Copper-Catalyzed Direct C-H Bond Arylation of Benzoxazoles with Anilines.Asian J. Org. Chem.2018, 7: 788-792.2018 Feb 19 online DOI:10.1002/ajoc.201800002.

[3] Yang S, Hu Y, Wang X, GaoY, Li K, Zhang X, Chen S,Zhang T, Gu J, Deng J. Deletion ofsigBCauses Increased Sensitivity to para-Aminosalicylic Acid and Sulfamethoxazole inMycobacterium tuberculosis.Antimicrob Agents Chemother.2017, 61(10):e00551-17.

[4] Ma J, Huang H, Xie Y, Liu Z, Zhao J, Zhang C, Jia Y, Zhang Y, Zhang H,Zhang T,Ju J. Biosynthesis of ilamycins featuring unusual building blocks and engineered production of enhanced anti-tuberculosis agents.Nat Commun.2017, 8(1):391.

[5] Lu X, Tang J, Cui S, Wan B, Franzblauc S,Zhang T, Zhang X, Ding K. Pyrazolo [1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity.E J Med Chem. 2017. 125: 41-48.

[6] Lu X, Hu X, Liu Z,Zhang T,Wang R, Wan B, Franzblaud S,You Q. Benzylsulfanyl benzo-heterocycle amides and hydrazones as new agents against drug susceptible and resistantMycobacterium tuberculosis.Med Chem Comm2017.8(6).

[7] He W, Zhou XJ Qin X, Mai Y, Lin X, Liao S, Yang B,Zhang T, Tu Z, Wang J, Liu Y. Quinone/hydroquinone meroterpenoids with antitubercular and cytotoxic activities produced by the sponge-derived fungusGliomastix sp. ZSDS1-F7.Nat Prod Res. 2017, 31(5):604-609.

[8] Lu X, Tang J, Liu Z, Li M,Zhang T, Zhang X, Ding K.Discovery of new chemical entities as potential leads againstMycobacterium tuberculosis.Bioorg Med Chem Lett.2016,26(24):5916-5919.

[9] Saremi L, Saremi M, Lotfipanah S, Mani S, Fu J,Zhang T. Correlation between HFE gene polymorphisms and increased risk of coronary artery disease among patients with type 2 diabetes in Iran.Turk J Med Sci. 2016,46(3):590-596.

[10] Wang J, Wei X, Qin X, Tian X, Liao L, Li K, Zhou X, Yang X, Wang F,Zhang T, Tu Z, Chen B, Liu Y. Antiviral Merosesquiterpenoids Produced by the Antarctic FungusAspergillus ochraceopetaliformisSCSIO 05702.J Nat Prod.2016, 79(1):59-65.

[11] Tian Y, Lin X, Wang Z, Zhou X, Qin X, Kaliyaperumal K,Zhang T, Tu Z, Liu Y. Asteltoxins with Antiviral Activities from the Marine Sponge-Derived FungusAspergillus sp.SCSIO XWS02F40.Molecules. 2015, 21(1):E34.

[12] Saremi L, Saremi M, Lotfipanah S, Imani S,Zhang T, Fu J.Relationship betweenPPARGC1AGene Polymorphisms with the Increased Risk of Coronary Artery Disease among Patients with Type 2 Diabetes Mellitus in Iran.Acta Endo (Buc)2015,11 (1): 13-17.

[13] Wang J, Qin X, Xu F,Zhang T, Liao S, Lin X,Yang B,Liu J,Wang L,Tu Z,Liu Y. Tetramic acid derivatives and polyphenols from sponge-derived fungus and their biological evaluation.Nat Prod Res.2015.9:1-5.

[14] Wang J, We X, Qin X, Chen H, Lin X,Zhang T, Yang X, Liao S, Yang B, Liu J, Zhou X, Tu Z, Liu Y. Two new prenylated phenols from endogenous fungusPestalotiopsis vacciniiof mangrove plantKandelia candel(L.) Druce.Phytochem Lett. 2015.12: 59–62.

[15] Wang J, Wang Z, Ju Z, Wan J, Liao S, Lin X,Zhang T, Zhou X, Chen H, Tu Z, Liu Y. Cytotoxic cytochalasins from marine-derived fungus Arthrinium arundinis.Planta Med. 2015, 81(2):160-166.

[16] Wang J, Lin X, Qin C, Liao S, Wan T,Zhang T, Liu J, Fredimoses M, Chen H, Yang B, Zhou X, Yang X, Tu Z, Liu Y. Antimicrobial and Antiviral Sesquiterpenoids from Sponge-Associated Fungus,Aspergillus sydowiiZSDS1-F6.J Antibiot. 2014,67(8):581-583.

[17] Sun J, Lin X, Zhou X, Wan T,Zhang T, Yang B, Yang X, Tu Z, Liu Y. Pestalols A-E, New Alkenyl Phenol and Benzaldehyde Derivatives from Endophytic FungusPestalotiopsis sp. Acbc2 Isolated from the Chinese Mangrove Plant.Aegiceras corniculatum.J Antibiot. 2014.67:451-457.

[18] Wang J, Xu F, Wang Z, Lu X, Wan J, Yang B, Zhou X,Zhang T, Tu Z, Liu Y.A new naphthalene glycoside from the sponge-derived fungusArthrinium sp.ZSDS1-F3.Nat Prod Res. 2014,16:1-5.

[19] Fang W, Lin X, Zhou X, Wan J, Lu X, Yang B, Ai W, Lin J,Zhang T, Tu Z, Liu Y. Cytotoxic and antiviral nitrobenzoyl sesquiterpenoids from the marine-derived fungusAspergillus ochraceusJcma1 F17.Med. Chem. Commun. 2014,5:701-705.

[20] Yang Z, Li R,Zhang T. Evolution of influenza aH7N9virus with an emphasis on gene constellation.J Genet Genomics. 2014,41:3-6.

[21]盧峰嶽，張天宇，譚耀駒，蔡杏珊，胡族瓊，劉燕文，蘇碧儀。吡嗪酰胺敏感性檢測結果應該運用到對結核病治療。廣東醫學。2015，36 (10): 1509-1511。

申請的發明專利

美國專利：

Eric Nuermberger,Tianyu Zhang, Jacques Grosset.Autoluminescent mycobacterial reporter strains，2011, patent number: (61/367,475).

PCT：

[1]陸小雲，湯健，丁克，張天宇，塗正超，伍甜，萬軍庭，曹元元。吡唑並[1,5-a]吡啶類化合物及其應用，2015，PCT (CN2015/086852)。

[2]張天宇，劉誌永。一種可投送自主發光元件的分枝杆菌噬菌體及其應用，2016，PCT（CN2016/081202）

[3]張天宇,劉洋。一種吡啶類化合物的新用途（2018）,專利申請號：PCT（CN2018/077992）。（申請提交日：2018-03-05）。

中國專利：

[1]張天宇，楊峰，劉佳。整合質粒pOPHI及無抗性篩選標記的自主發光分枝杆菌（2012）,專利號：ZL 201210183007.2。授權證書號：1296049,授權公告日：2013-10-30。

[2]張天宇，楊峰，鄒文英。一種用於高效構建無抗性標記重組分枝杆菌的抗性表達盒（2013）,專利號：ZL 201310386264.0。授權證書號：1799902,授權公告日：2015-09-23。

[3]朱強，張天宇，劉蘭英，魯明輝，毛婷婷，黃金波。吲哚[3,2-c]喹啉類化合物或其藥學上可接受的鹽及其製備方法和應用（2013），ZL 201310385431.X。授權證書號：2017232,授權公告日：2016-04-06。

[4]丁克，陸小雲，張天宇，湯健，魯明輝，李宇鵬，張章，梁鎮興，錢政江。N-4-三氟甲基苯基水楊酰胺衍生物的製備方法和應用（2014），專利申請號：201410073672.5。

[5]陸小雲，湯健，丁克，張天宇，塗正超，伍甜，萬軍庭，曹元元。吡唑並[1,5-a]吡啶類化合物及其應用(2014)，專利申請號：201410562805.5 [優先權專利號更改為2015104607516]。

[6]張天宇，曹元元，伍甜，譚守勇，譚耀駒，蔡杏珊，劉春平。構建無選擇標記的自主發光膿腫分枝杆菌的方法及建立相應體外高通量篩藥模型(2015)，專利申請號：ZL201510104936.3。(2018.06.01已授權)

[7]張天宇，劉誌永。一種可投送自主發光元件的分枝杆菌噬菌體及其應用(2016)，專利申請號：201610127984.9。[抗結核候選藥怡萊黴素申請了專利（201610885104.4）及發表了高水平的論文（Nat. Commun., 2017, 8, 391），研究成果發表以後受到了國家新華網、科技日報、國家自然科學基金委等國家級媒體的報道，並被收錄國家自然科學基金委資助成果一書及入選“中國海洋與湖沼學會“2017年十大科技進展”]

[8]鞠建華，馬俊英，張天宇，劉誌永。一種海洋鏈黴菌及其環肽化合物在製備抗結核分枝杆菌藥物中的應用（2016），專利申請號：201610255638.9。

[9]張天宇，摩西·M·恩紮瑞，王邦興，劉誌永，韓軼，劉燕，劉洋。一種檢測結核分支杆菌耐藥性的DNA標記物及其應用(2016)，專利申請號：201610564946.X。

[10]塗正超（475345840（美國護照），朱強，張天宇，黃金波，徐曉冰，萬軍庭，黎敏科，李登科，周亞麗，劉誌永，王邦興，米琦.托特雷拉。吲哚-2-酮-3-螺噻嗪酮或噻唑酮化合物及其應用(2016)，專利申請號：2016106571617。(申請提交日：2016-8-11)

[11]張天宇,馬格文如.朱麗俄斯，劉燕，王邦興，曹元元，黃少波，瑪卡芬.蓋樂,張洋，郭錦濤，柴然吉比.籌多拉瑞，劉洋。一種硫鏈絲菌素-慶大黴素抗性基因體係及含有其的抗性表達盒和重組質粒（2016），專利申請號：201610902985.6。(申請提交日：2016-10-18，發文序號：2016101801161450)（公告日：專利申請公布和進入實質審查日：2017-05-17）

[12]張天宇,劉洋，譚守勇，劉健雄，李昕潔，王邦興，周佩佩，蔡杏珊，郭玲敏，劉燕，劉誌永，唐運祥，高亞敏，薑火鳳。吡唑並[1,5-a]吡啶類化合物的新應用及一種治療膿腫分枝杆菌感染的藥物組合物（2017），專利申請號：201710240224.3。(申請提交日：2017-04-13)

[13]王子厚，張天宇，馬領弟，陳昌紅。蠟梅屬植物抗結核杆菌的用途(2017),專利申請號：201710392913.6。(申請提交日：2017-05-27)

[14]鄢明，張天宇，張妞妞，劉誌永，錢露，唐運祥，程亞娟，張學景。間二取代苯酚化合物及其製備方法與抗結核菌應用(2017),專利申請號：201711310722.7。（申請提交日：2017-12-11）。

[15]羅有福，張天宇。新型小分子化合物、製備方法及在製備抗耐藥結核分枝杆菌等分枝杆菌藥物方麵的用途（2018）,專利申請號：201810003576.1。（申請提交日：2018-01-04）。

[16]張天宇,劉洋。一種吡啶類化合物的新用途（2018）,專利申請號：201810106538.9。（申請提交日：2018-02-02）。

[17]張天宇,劉燕，孫彩軍，潘恩祥，王邦興，郭靈敏，陳淩，劉誌永。一種艾滋病疫苗及其製備方法（2018）,專利申請號：201810359440.4。（申請提交日：2018-04-20）。

[18]羅有福，張天宇。嘧啶類小分子化合物及在製備抗分枝杆菌藥物中的用途（2018），專利申請號：201810574690.X。（申請提交日：2018-06-06）。